Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recigen for treatment of COVID-19
IRCT20150914024017N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Mar 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in coronavirus disease 2019 (COVID-19) comparing Recigen with Placebo (2 arms). Primary endpoints: hospital stay days, need for ICU admission and 1 more. Started Mar 2020; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20150914024017N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150914024017N1.